Substituted xanthine derivatives
This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
1. A method of treating a disease or condition in a patient in need thereof, comprising administering to the patient an effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from —CH 3 and —CD 3 ;
R 2 is selected from —CH 3 and —CD 3 ; Y 1 is deuterium or hydrogen, wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000, wherein the disease is selected from insulin dependent diabetes, non-insulin dependent diabetes, metabolic syndrome, obesity, insulin resistance, dyslipidemia, pathological glucose tolerance, hypertension, hyperlipidemia, hyperuricemia, gout, and hypercoagulability.
2. The method of claim 1 , wherein R 1 is —CH 3 .
3. The method of claim 1 , wherein R 1 is —CD 3 .
4. The method of claim 1 , wherein R 2 is —CH 3 .
5. The method of claim 1 , wherein R 2 is —CD 3 .
6. The method of claim 1 , wherein Y 1 is deuterium.
7. The method of claim 1 , wherein Y 1 is hydrogen.
8. The method of claim 1 , wherein the compound is selected from the group consisting of the following compounds:
or a pharmaceutically acceptable salt thereof.
9. A method of treating a disease or condition in a patient in need thereof, comprising administering to the patient an effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from —CH 3 and —CD 3 ;
R 2 is selected from —CH 3 and —CD 3 ; Y 1 is deuterium or hydrogen;
with the proviso that
(i) if Y 1 is deuterium, then R 2 is CD 3 ; and
(ii) if Y 1 is hydrogen, then R 1 is CH 3 ,
wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000, wherein the disease is selected from insulin dependent diabetes, non-insulin dependent diabetes, metabolic syndrome, obesity, insulin resistance, dyslipidemia, pathological glucose tolerance, hypertension, hyperlipidemia, hyperuricemia, gout, and hypercoagulability.
10. The method of claim 9 , wherein R 1 is —CH 3 .
11. The method of claim 9 , wherein R 1 is —CD 3 .
12. The method of claim 9 , wherein R 2 is —CH 3 .
13. The method of claim 9 , wherein R 2 is —CD 3 .
14. The method of claim 9 , wherein Y 1 is deuterium.
15. The method of claim 9 , wherein Y 1 is hydrogen.
16. The method of claim 9 , wherein the compound is selected from the group consisting of the following compounds:
or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein any atom not designated as deuterium is present at its natural isotopic abundance, and the isotopic enrichment factor for each designated deuterium atom is at least 6000.
18. The method of claim 9 , wherein any atom not designated as deuterium is present at its natural isotopic abundance, and the isotopic enrichment factor for each designated deuterium atom is at least 6000.
19. The method of claim 17 , wherein the isotopic enrichment factor for each designated deuterium atom is at least 6333.3.
20. The method of claim 18 , wherein the isotopic enrichment factor for each designated deuterium atom is at least 6333.3.